Cigna Corporation

🇺🇸New York Stock Exchange
Back to all articles
Cigna Corporation stock analysis CI overview
Bullish +75

Cigna: Flashing A Buy For Dividend Growth And Deep Value

📈 Cigna Group (CI) maintains a 'Buy' rating with catalysts for double-digit adjusted income per share growth expected to resume in 2027 and beyond.

💊 Growth drivers include expansion in the pharmacy segment, biosimilar adoption, behavioral health services, and aggressive share buybacks.

📊 The stock trades at an 8.5x forward P/E, representing a 29% discount to fair value.

🏦 Investors project a potential 17% annual total return for Cigna through the year 2031 based on current valuation metrics.

🤲 Dividend safety is highlighted by a low-20% payout ratio and an A+ Quant grade, indicating robust capacity for dividend growth.

👨‍💼 Scott Kaufman of Dividend Kings describes the company as having the financial anatomy typical of high-quality dividend growers with dominant market position.

⚠️ The author discloses a beneficial long position in Cigna shares but notes they did not receive compensation specifically for this article.

⚖️ Seeking Alpha and its third-party analysts disclaim that past performance is no guarantee of future results.

📉 No formal investment recommendation or suitability advice is given regarding whether the stock fits an individual investor's specific portfolio needs.

🔒 Seeking Alpha clarifies it is not a licensed securities dealer, broker, or US investment adviser.

Bullish Signals
  • Cigna Group remains a Buy rating with catalysts for double-digit adjusted income per share growth expected to resume in 2027 and beyond.
  • Pharmacy segment, biosimilar adoption, behavioral health expansion, and aggressive share buybacks are driving both topline and margin growth.
  • Shares trade at an 8.5x forward P/E, representing a 29% discount to fair value, which supports a projected 17% annual total return through 2031.
  • Dividend safety is robust with a low-20% payout ratio and A+ Quant grade, positioning CI for continued, accelerating dividend growth.
Risk Factors
  • No negative points or risks were identified in this article; the entire text is positive, focusing on buy recommendations, growth catalysts, undervaluation, dividend safety, and analyst credentials.
  • The article contains an analyst disclosure stating they have a beneficial long position in Cigna shares, which creates a potential conflict of interest that could bias the bullish recommendation.
Full Analysis
The Cigna Group (CI) is evaluated as a Buy, primarily based on anticipated double-digit adjusted income per share growth expected to resume in 2027 and beyond. Key drivers for this top-line and margin expansion include growth in the pharmacy segment, adoption of biosimilars, behavioral health expansion, and aggressive share buybacks. The stock currently trades at an 8.5x forward P/E ratio, which represents a 29% discount to its estimated fair value, supporting a projected annual total return of 17% through 2031. Dividend safety is considered robust for Cigna, characterized by a low-20% payout ratio and an A+ Quant grade, positioning the company for continued and accelerating dividend growth. The analysis emphasizes the importance of specific financial anatomy when evaluating newcomers to the dividend growth sector, highlighting factors such as a dominant market position, a payout ratio that provides room for error, and a management team capable of driving value creation. Scott Kaufman serves as the lead analyst for Dividend Kings and brings over a decade of experience in the financial sector to his analysis. He aims to provide actionable insights into high-quality dividend growth and undervalued opportunities to secure robust total returns through cash dividends and strong capital gains. The team behind this analysis includes Kody's Dividends, Justin Law, and Rachel Kaufman. The author holds a beneficial long position in Cigna shares either through stock ownership or derivatives but states he is not receiving compensation for the article other than from Seeking Alpha. Seeking Alpha discloses that analysts are third-party authors who may not be licensed or certified by regulatory bodies and notes that past performance does not guarantee future results.